S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals - ATNM Price Target & Analyst Ratings

$12.21
+0.28 (+2.35%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.75
$12.25
50-Day Range
N/A
52-Week Range
$4.41
$15.12
Volume
219,850 shs
Average Volume
284,816 shs
Market Capitalization
$311.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.50

Actinium Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$31.50
157.99% Upside
High Prediction$53.00
Average Prediction$31.50
Low Prediction$18.00
TypeCurrent
2/4/22 to 2/4/23
1 Month Ago
1/5/22 to 1/5/23
3 Months Ago
11/6/21 to 11/6/22
1 Year Ago
2/4/21 to 2/4/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$31.50$31.50$31.50$31.67
Predicted Upside157.99% Upside234.34% Upside234.34% Upside333.59% Upside
Get Actinium Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

ATNM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATNM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Actinium Pharmaceuticals Stock vs. The Competition

TypeActinium PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside157.99% Upside2,513.81% Upside8.56% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$25.00 ➝ $35.00+233.65%
10/31/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Zhi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$16.00 ➝ $18.00+71.59%
10/31/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$45.00 ➝ $53.00+444.71%
9/8/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$20.00+166.31%
9/15/2021Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$20.00 ➝ $25.00+266.57%
12/31/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
(Data available from 2/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ATNM Price Target - Frequently Asked Questions

What is Actinium Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Actinium Pharmaceuticals stock is Buy based on the current 3 buy ratings for ATNM. The average twelve-month price prediction for Actinium Pharmaceuticals is $31.50 with a high price target of $53.00 and a low price target of $18.00. Learn more on ATNM's analyst rating history.

Do Wall Street analysts like Actinium Pharmaceuticals more than its competitors?

Analysts like Actinium Pharmaceuticals more than other Medical companies. The consensus rating score for Actinium Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how ATNM compares to other companies.

Does Actinium Pharmaceuticals's stock price have much upside?

According to analysts, Actinium Pharmaceuticals's stock has a predicted upside of 234.34% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NYSEAMERICAN:ATNM) was last updated on 2/4/2023 by MarketBeat.com Staff